Disclosed are stable formulations comprising an active ingredient belonging to the amino acid, peptide or protein classes and glycerin or mixtures thereof with water, characterised by a low iron and aldehyde and/or ketone species content. The invention also relates to the use of said purified glycerin and processes for the preparation of said formulations comprising a quantitation step of the iron and aldehyde and/or ketone species content in glycerin.
The present invention relates to a device for dispensing (1) liquid or semi-solid products, particularly medicines, medical devices or cosmetic products. According to the invention, this device comprises: - an actuator button (2) configured to be coupled to a dispensing valve of a container of a liquid or semi-solid product, and comprising a first connector (3); - a dispensing accessory (10, 20, 30) comprising a second connector (4) and a dispensing mouth (5); where said first connector (3) and said second connector (4) can be removably coupled one to the other for connecting, in a coupling configuration, said dispensing accessory (10, 20, 30) to said actuator button (2), and where, in said coupling configuration, the pressing of said actuator button (2) is capable of activating said dispensing valve of said container to dispense a quantity of said liquid or semi-solid product from said dispensing mouth (5) of said dispensing accessory (10, 20, 30).
B05B 1/26 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage avec des moyens pour briser ou dévier mécaniquement le jet à sa sortie, p. ex. des déflecteurs fixesDispersion du liquide ou d'autre matériau fluide sortant à l'aide de jets d'impact
The present invention relates to an improved container (1) for ampoules or syringes (50) comprising a primary case (10) provided with at least one opening (11) closable by means of a primary lid (12), and a tray (30) comprising a plurality of seats (31) configured to accommodate the same number of ampoules or syringes (50), further comprising a secondary lid (21) which defines, inside said primary case (10), a secondary case (20) which, in turn, accommodates in its interior said tray (30), so that when said tray (30) is inserted inside said secondary case (20), the ampoules or syringes (50) contained therein face towards the inner face of said secondary lid (21), on said secondary lid (21) being defined, at each ampoule or syringe (50) below it, an access opening (24) closed by a removable closure portion (23), characterised in that each of said closure portions (23) comprises a gripping zone (25) defined by means of a further transverse break line (26) arranged transversely with respect to the width of the closure portion (23) so that the user can break said further transverse break line (26) by applying pressure at the surface of the gripping zone (25) and more easily remove the closure portion (23) in order to access the underlying ampoule or syringe (50).
B65D 5/02 - Réceptacles de section transversale polygonale rigides ou semi-rigides, p. ex. boîtes, cartons ou plateaux, formés en pliant ou montant un ou plusieurs flans de papier en pliant ou montant un seul flan pour former un corps tubulaire avec ou sans pliage subséquent, ou par addition d'éléments séparés, pour fermer les extrémités du corps
B65D 5/50 - Éléments internes de support ou de protection du contenu
B65D 5/54 - Lignes de moindre résistance facilitant l'ouverture des réceptacles ou leur division en parties séparées, par découpage ou déchirement
B65D 75/58 - Dispositifs d'ouverture ou servant à retirer le contenu, ajoutés ou incorporés lors de la confection du paquet
B65D 85/42 - Réceptacles, éléments d'emballage ou paquets spécialement adaptés à des objets ou à des matériaux particuliers pour objets particulièrement sensibles aux dommages par chocs ou compression pour ampoules de médicaments pour ampoules électriquesRéceptacles, éléments d'emballage ou paquets spécialement adaptés à des objets ou à des matériaux particuliers pour objets particulièrement sensibles aux dommages par chocs ou compression pour valves ou tubes électroniques
B65D 51/20 - Capuchons, couvercles ou chapeaux fonctionnant avec une fermeture intérieure disposée pour être ouverte en perçant, coupant ou déchirant
A61J 7/00 - Dispositifs pour administrer les médicaments par voie buccale, p. ex. cuillèresDispositifs pour compter les pilulesDispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments
4.
USE OF THYROID HORMONE T4 IN A HIGH VERSATILITY TREATMENT IN PATIENTS TAKING PROTON PUMP INHIBITORS
The present document describes the medical use of an ethanol-free glycerol solution of thyroid hormone T4 in the treatment or prevention of a pathological condition related to an abnormal functioning of the thyroid hormone in patients under treatment with a proton pump inhibitor, wherein both treatments with hormone T4 and with proton pump inhibitor are performed orally. Unexpectedly with respect to what was previously known, the oral absorption of T4 from the present solution is not affected by the administration of proton pump inhibitor, therefore the two medicaments can be administered independently of one another, without any limitation regarding the mutual administration schedules.
The present invention relates to the use of Salvia haenkei extract as an active agent in the treatment of musculoskeletal disorders, being able to offer a significant contribution in slowing, relieving, reducing and/or preventing alterations and damages of the musculoskeletal tissues. Furthermore, the present invention also relates to a pharmaceutical composition comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of musculoskeletal disorders.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
7.
DICLOFENAC TOPICAL FORMULATION WITH A HIGH ABSORPTION RATE
Pharmaceutical compositions for topical use comprising diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing to carry out treatments requiring the administration of high and accurate dosages.
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
8.
Effects of Heparin on Topical Use of Plasters Containing a Non-Steroidal Anti-Inflammatory Drug
The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
Disclosed are solid orodispersible pharmaceutical compositions in film form for oral administration of lorazepam, characterised by high stability throughout the shelf life of the product. The compositions disclosed are suitable for administration even to unconscious or dysphagic patients.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
Disclosed is a process for the preparation of hydrogels consisting of crosslinked glycosaminoglycans, which comprises:
a) reacting at least one hybrid cooperative complex obtained by heating aqueous solutions of low- and high-molecular-weight glycosaminoglycans at 80-160° C. with a diepoxide as crosslinker in a ratio with the complex ranging between 0.1 and 1 equivalents, preferably between 0.2 and 0.4 equivalents, the concentration by weight of the complex in the solution ranging between 1% and 15%, preferably between 2% and 10%;
b) purifying by dialysis, ultrafiltration and diafiltration.
Disclosed are soluble polyelectrolyte complexes of polymeric biguanidine antimicrobial, such as polyhexamethylene biguanide or polyaminopropyl biguanide, with glycosaminoglycans, such as hyaluronic acid, chondroitin or chondroitin sulphate and derivatives thereof, and their use as active ingredients of pharmaceutical compositions or medical devices.
New administration regimens of the T4 thyroid hormone are described, characterized by the use of alcohol-free, water-glycerol solutions of said hormone, administered at short temporal distance, i.e. within less than 30 minutes, typically between 15 and less than 30 minutes, from the closest consumed meal.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4
14.
HOLLOW MICRONEEDLE FOR TRANSDERMAL DELIVERY OF ACTIVE MOLECULES AND/OR FOR THE SAMPLING OF BIOLOGICAL FLUIDS AND MANUFACTURING METHOD OF SUCH HOLLOW MICRONEEDLE
The present invention relates to a micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. The micro-needle (7; 8; 9) is made of polymeric material through photolithography. A cavity is defined in the micro-needle (7; 8; 9).
The present invention relates to a micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. The micro-needle (7; 8; 9) is made of polymeric material through photolithography. A cavity is defined in the micro-needle (7; 8; 9).
The present invention further relates to a method for obtaining through photolithography at least one micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. A photo-cross linking polymer is exposed in liquid phase to an energy radiation causing the hardening thereof. A photolithographic mask (1; 2) is interposed between the source of the energy radiation and the photo-cross linking polymer. The photolithographic mask (1; 2) is configured in a manner such to generate in the photo-cross linking polymer a peripheral shadow area, a central shadow area and a lighting area confined between the peripheral shadow area and the central shadow area.
The present invention relates to a micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. The micro-needle (7; 8; 9) is made of polymeric material through photolithography. A cavity is defined in the micro-needle (7; 8; 9).
The present invention further relates to a method for obtaining through photolithography at least one micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. A photo-cross linking polymer is exposed in liquid phase to an energy radiation causing the hardening thereof. A photolithographic mask (1; 2) is interposed between the source of the energy radiation and the photo-cross linking polymer. The photolithographic mask (1; 2) is configured in a manner such to generate in the photo-cross linking polymer a peripheral shadow area, a central shadow area and a lighting area confined between the peripheral shadow area and the central shadow area.
The method according to this invention is aimed at obtaining a micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids which shows the peculiar characteristic of being hollow and which is manufactured by means of a single photolithography operation, thus avoiding the use of additional processing.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
Corynebacterium parvumCorynebacterium parvum included in a matrix comprising hyaluronic acid or salts thereof. The compositions of the invention are endowed with antiviral and immunostimulant properties and may advantageously administered for the prevention and treatment of infection by viruses and other infective agents. The compositions, in form of gels, liquids or powders, may be administered by the inhalatory, topical or systemic route.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
16.
INJECTABLE MIXTURES OF HYALURONIC ACID FOR USE IN DERMO-AESTHETICS
Disclosed are injectable dermo-aesthetic formulations comprising aqueous solutions of at least one unmodified high-molecular-weight linear hyaluronic acid or hyaluronate and at least one unmodified low-molecular-weight linear hyaluronic acid or hyaluronate or non-sulphated chondroitin. The compositions according to the invention are useful as fillers with an excellent safety profile, adequate residence time at the site of application, and limited extrusion force.
Disclosed are intra-articular compositions comprising at least one low-molecular-weight linear hyaluronic acid or hyaluronate and at least one high-molecular-weight linear hyaluronic acid or hyaluronate, said compositions being characterised by a dynamic viscosity ranging between 10 and 60 Pa*s (at 0.01 s-1), a crossover frequency ranging between 1 and 10 rad/s, and a value of the viscous and elastic moduli at the crossover frequency ranging between 20 and 110 Pa.
A plunger is described, which is configured for application in a syringe-type pump for a machine for encapsulation of soft capsules, for adjusting the quantity of filler to be injected into said soft capsules, said plunger having an axially developing structure and comprising: -a tip (31) and a sealing body (32) connected to the tip, adapted to penetrate into said syringe-type pump (P), - a first mechanical abutment ring (33), fixedly positioned, connected to said sealing body, - a plunger stopper housing (34), connected to said fixedly positioned mechanical abutment ring, - a second mechanical abutment ring (35), axially adjustable, - a mechanical dowel (37) protruding from said stopper housing, - an adjuster nut (36) adapted to be screwed on said mechanical dowel (37) for adjusting the axial position of the second ring (35) relative to the first ring, so as to adjust the axial position of the plunger in said syringe-type pump (P).
A61J 3/07 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de capsules ou de petits conteneurs similaires à absorber par voie buccale
19.
ADMINISTRATION REGIMEN OF SOLUTIONS OF T4 THYROID HORMONE WITH HIGH ORAL ABSORPTION
New administration regimens of the T4 thyroid hormone are described, characterized by the use of alcohol-free, water-glycerol solutions of said hormone, administered at short temporal distance, i.e. within less than 30 minutes, typically between 15 and less than 30 minutes, from the closest consumed meal.
Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.
Disclosed are pharmaceutical or nutraceutical compositions comprising the peptide having the sequence NMYLPPVPPP PVVPTF or extracts containing it, in admixture with suitable excipients.
A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
A61P 15/10 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour l'impuissance
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
22.
SYNERGISTICALLY COOPERATIVE COMPOSITIONS USEFUL FOR SOFT TISSUE AUGMENTATION, DRUG DELIVERY AND RELATED FIELDS
The present invention relates to compositions based on: (a) a glycosaminoglycan or mixtures thereof;(b) one or more tocopherols, tocotrienols and mixtures thereof; (c) a selected stabilizer. The composition is in solution form, with the above agents being present within specific concentration ranges, without being engaged in formal chemical binding with each other. The component (a) can be e.g. hyaluronic acid (HA) or a salt thereof; the component (b) can be a polyether clathratee.g. a cyclodextrin, or a combination of a fatty acid with an emulsifier; the component (c) can be one or more among α- tocopherols, β-tocopherols, γ-tocopherols, δ-tocopherols; α-tocotrienols, β-tocotrienols, γ-tocotrienols, δ-tocotrienols; preferably the component (c) is vitamin E. In the present compositions, the above agents strongly cooperate to provide enhanced and more stable viscoelastic properties, resulting in a product with higher resistant to thermal treatments like e.g. heat-sterilization, autoclaving, etc. The present compositions, optionally loaded with pharmaceutically and/or cosmetically active agents, are advantageously used in medical or cosmetic methods.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
23.
HOLLOW MICRONEEDLE FOR TRANSDERMAL DELIVERY OF ACTIVE MOLECULES AND/OR FOR THE SAMPLING OF BIOLOGICAL FLUIDS AND MANUFACTURING METHOD OF SUCH HOLLOW MICRONEEDLE
The present invention relates to a micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. The micro-needle (7; 8; 9) is made of polymeric material through photolithography. A cavity is defined in the micro-needle (7; 8; 9). The present invention further relates to a method for obtaining through photolithography at least one micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids. A photo-cross linking polymer is exposed in liquid phase to an energy radiation causing the hardening thereof. A photolithographic mask (1; 2) is interposed between the source of the energy radiation and the photo- cross linking polymer. The photolithographic mask (1; 2) is configured in a manner such to generate in the photo-cross linking polymer a peripheral shadow area, a central shadow area and a lighting area confined between the peripheral shadow area and the central shadow area. The method according to this invention is aimed at obtaining a micro-needle (7; 8; 9) for the transdermal administration of active molecules and/or for the sampling of biological fluids which shows the peculiar characteristic of being hollow and which is manufactured by means of a single photolithography operation, thus avoiding the use of additional processing.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
B81C 1/00 - Fabrication ou traitement de dispositifs ou de systèmes dans ou sur un substrat
24.
HIGHLY STABLE FORMULATIONS OF THYROID HORMONE IN SOFT CAPSULES
New soft capsules are described having within them a fill comprising thyroid hormones (thyroxine T4 or triiodothyronine T3) and a high amylose-starch, optionally associated with vegetable hydrocolloids and/or glycerol. Compared to traditional capsules, these capsules have a strong and unexpected increase in the stability of T4 or T3 during storage.
The use of Salvia haenkei extract is described as a re-epithelizing and cicatrizing agent in the treatment of tissue lesions. Pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients for use in the treatment of tissue lesions are also disclosed.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
26.
USE OF A VEGETAL EXTRACT AS AN ACTIVE AGENT IN THE TREATMENT OF DERMATOLOGICAL DISEASES
Salvia haenkeiSalvia haenkeiSalvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of dermatological diseases.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
27.
Method for decontaminating a biological material by partitioning and inactivation
The invention relates to a process for decontaminating a biological material by partitioning and inactivation techniques. The process includes the formation of a three-layer liquid system (a-b-c), where the layers are placed one onto the other and are different from each other in density and/or miscibility properties. The upper layer (a) has an aqueous solution of the biological material to decontaminate; the lower layer (c) has the solution inactivating viruses, prions or bacteria; the intermediate layer (b), interposed between the upper and lower layers, separates and protects the biological material from the inactivating solution which has an organic solvent or a mixture of more such solvents, immiscible at least with the upper layer. Moreover, the invention provides specific indications about the density difference between the layers in order to preserve system stability and, at the same time, protect the efficiency of decontamination and the biological activity of the material undergoing decontamination.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
Disclosed is a process for the preparation of hydrogels consisting of crosslinked glycosaminoglycans, which comprises: a) reacting at least one hybrid cooperative complex obtained by heating aqueous solutions of low- and high-molecular- weight glycosaminoglycans at 80-160°C with a diepoxide as crosslinker in a ratio with the complex ranging between 0.1 and 1 equivalents, preferably between 0.2 and 0.4 equivalents, the concentration by weight of the complex in the solution ranging between 1% and 15%, preferably between 2% and 10%; b) purifying by dialysis, ultrafiltration and diafiltration.
New soft gelatin capsules highly protected against the degradation of the active ingredient contained therein and highly resistant to hydration are described. The capsular wall is characterized by containing hydroxypropyl beta cyclodextrin in low quantity with respect to the weight of the wall and sub-stoichiometric with respect to that necessary for complexing the drug contained within the capsule. The new capsules are storage-stable, avoid the development of active ingredient by-products and maintain a high weight constancy, i.e. low hygroscopy.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
30.
Closure assembly for bottle, associated bottle and assembly method
A closure assembly for a bottle including a cage, a closure cap, and a sealing nut. The cage includes a side wall with an inner surface including a first annular relief and a second annular relief spaced so as to form a seat for a collar of the bottle. The closure cap includes a head and a shank. The sealing nut includes a side wall. The inner surface of the side wall of the cage includes one or more retaining teeth for retaining the head of the closure cap. The retaining teeth are cantilevered and inclined with respect to the inner surface of the side wall of the cage. Opposite the retaining teeth a recess is provided within which the teeth can be retracted, so that the head of the sealing cap can be pushed towards the base of the cage.
B65D 51/28 - Fermetures non prévues ailleurs combinées avec dispositifs auxiliaires pour des buts autres que la fermeture avec réceptacles auxiliaires pour objets ou matériaux supplémentaires
31.
HIGH-STABILITY PACKAGED SOLUTIONS OF T4 THYROID HORMONE
The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones,in which a number of layers of specific materials separate the solution from contact with the external environment.
The invention relates to a new process for decontaminating a biological material by partitioning and inactivation techniques. The process comprises the formation of a three-layer liquid system (a-b-c), where the layers are placed one onto the other and are different from each other in density and/or miscibility properties; the upper layer (a) comprises an aqueous solution of the biological material to decontaminate; the lower layer (c) comprises the solution inactivating said viruses, prions or bacteria; the intermediate layer (b), interposed between said upper and lower layers, separates and protects the biological material from the inactivating solution; it is studied so as to maximize the stability of the three-layer system in all the steps of the decontamination process; it comprises an organic solvent (or a mixture of more such solvents), immiscible at least with the upper layer; preferred organic solvents and their mixing proportions are specified in the description. Moreover, the invention provides specific indications about the density difference between the layers in order to preserve system stability and, at the same time, protect the efficiency of decontamination and the biological activity of the material undergoing decontamination.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p. ex. adaptation de la température, irradiation
The invention relates to a new composite based on hydroxypropyl-β-cyclodextrin, sucralose, a pharmaceutically active ingredient (API) complexed in said hydroxypropyl-β-cyclodextrin, and optionally an aqueous vehicle. The composite is obtainable by a complexation process of the API in hydroxypropyl-β-cyclodextrin, carried out in the presence of sucralose. The composite ensures a surprisingly high API bioavailability through buccal route of absorption, due to a high absorption rate through the oral membrane. The composite is therefore suitable for the preparation of oromucosal pharmaceutical compositions, e.g. buccal or sublingual tablets, orodispersible film, etc., having high bioavailability.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
Disclosed are soft gelatin capsules comprising a gelatin shell, a plasticiser, water, and optionally a calcium salt and a filling containing a dispersed or solubilised medicament comprising gelatin with gelling power, hydrolysed gelatin, glycerol, water, pectin and gellan gum. The formulations according to the invention allow gradual release of the active ingredient, regardless of pH.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
35.
Method for sealingly closing a bottle and associated sealingly closed bottle
A method for sealingly closing a bottle (1) is described, the method comprising the steps of: providing a cage (1009, a closing stopper (200) and a capsule (300); joining the stopper to the cage and the cage to the capsule (300), obtaining a preassembled closing assembly; aligning the closing assembly on the mouth of the bottle and exerting a pressure so as to sealingly close the bottle, wherein the annular relief of the cage (100) comes into contact with the bottle before the stopper comes into contact with the bottle.
B67B 1/08 - Fixation des bouchons qui sont maintenus en position par la pression qu'exercent sur le goulot de la bouteille des dispositifs ad hoc, p. ex. bouchons à bascule des bouteilles de bière
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
B65D 45/32 - Dispositifs de serrage ou autres dispositifs presseurs pour fixer ou retenir les éléments de fermeture exerçant une pression radiale, p. ex. bandes contractables encerclant l'élément de fermeture
Disclosed are ophthalmic formulations which use complexescalled L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.
New method to assess chromosomal imbalances in autosomal and gonosomal genomic DNA, via CGH technique, involving the use of a single array per DNA sample to be tested is described. The method, involving a strong reduction in the number of hybridization reactions, is most advantageously applicable to the determination of chromosomal imbalances in DNA samples whose sex is not known beforehand, such as happening in case of e.g. IVF protocols. The invention further includes data processing aimed at reducing the bias and to control the quality of the reference DNA used in the method. Supports and kits for performing the method are also provided.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
38.
LIQUID PHARMACEUTICAL FORMULATIONS OF TETRAIODOTHYRONINE
Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.
The present invention relates to a downstream industrial method of purifying chondroitin sulphate obtained from animal cartilage, which produces a product fully compliant with the specifications required for the use of said compound in the pharmaceutical field.
There is described a process for the extraction of human chorionic gonadotropin (hCG) starting from urine of pregnant women, or crude fraction thereof, comprising steps of ion exchange chromatography (particle size 50-500 µm), dye affinity chromatography, ultra/nanofiltration. The process allows the high-yield extraction of hCG having high activity; unlike known processes, it reduces/eliminates the preliminary steps of urine purification preceding chromatography, with no impact on the final product quality.
A composition for topical application characterized in that it includes, in a hydrogel base, vanillyl butyl ether and menthol. The composition described herein produces an ordered development of cold and warm sensations, obtaining effects that are particularly useful in the treatment of painful disorders of neurological and/ or muscular origin. The composition has further moisturizing and soothing effects that concur to an effect that is also curative, i.e., not simply symptomatic, of rheumatic and muscular pain, trauma and bruises. The composition is compatible with each administration form, being preferably and advantageously formulated as a plaster.
A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
42.
TOPICAL PREPARATIONS COMPRISING HYALURONIC ACID, VERBASCOSIDE AND GLYCEROPHOSPHOINOSITOL
The present invention relates to new synergistic associations of hyaluronic acid sodium salt (HANa), verbascoside (VB) and glycero-phospho-inositol (GPI), and the use of said associations in therapy, in particular in the topical treatment of inflammatory and painful conditions of the mucosa and/ or skin, such as dermatitis, acne, psoriasis, ulcers, decubitus ulcers, phlebitis, hemorrhoids, and in particular vulvodynia and urethritis.
The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus pathologies.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HPβCD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HPβCD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
METHOD AND DEVICE FOR MEASURING AND CONTROLLING THE DOSAGE OF SMALL QUANTITIES OF FLUID BY MEANS OF A RESONATING NEEDLE, AND RESONATING NEEDLE SUITABLE FOR THIS PURPOSE
A resonating needle is described, which is adapted to be used in a device for measuring and controlling the dosage of a small quantity of fluid, and which comprises: a needle (1) adapted to contain said small quantity of fluid; a resonating element of the piezoelectric type (2), coupled to said needle and adapted to be energized in order to detect variations of oscillation parameters of the needle and of the resonating element for the purpose of determining said dosage measurement and control.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
46.
CHONDROITIN COMPLEXES FOR TRANSCUTANEOUS ABSORPTION
The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.
Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and antimicrobial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.
The invention relates to a method for evaluating molecules in biological samples using microarray derived images, in particular to estimate differences in DNA sequences between a sample to be tested and a reference sample, wherein a support chip or slide (5) including a microarray (4) of objects or spots (3) is subjected to an acquisition step for obtaining a digital file of image data (IMG) derived from the microarray (4), to be processed by computer means (1). At least the following steps are envisaged: - identification of the spots (3) of the microarray (4) in the digital file of image data (IMG); - identification of the edges (15) or limits of each spot (3) by means of a chromatic contrast algorithm; - assigning a morphological parameter to each evaluated spot (3); - removal from the image data (IMG) file of all the spots (3) having a morphology parameter value lower than a predetermined value; - evaluation of statistical information available for each spot (3); - assigning to each spot (3) a quality parameter value derived from said statistical information; - excluding from further processing all the spots (3) having an assigned quality parameter value lower than a predetermined value.
G06F 19/20 - pour l'hybridation ou l'expression génique, p.ex. microréseaux, séquençage par hybridation, normalisation, profilage, modèles de correction de bruit, estimation du ratio d'expression, conception ou optimisation de sonde
Disclosed is a process for the production of chondroitin sulphate, wherein N-acetyl-galactosamine residues sulphated at the 4- or 6-positions are present on the same polysaccharide chain.
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
C07H 5/04 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure à l'azote
A multilayer structure for the packaging of biomedical films, in particular oral films, is described, said multilayer structure comprising cold-adhesive laminates and at least partly non-adhesive supporting layers which are organized in a specific stratified structure. The film packaged therein is effectively isolated from the external environment and protected from accidental mechanical stresses; the packaging process is low-cost and particularly attentive to the delicate structural characteristics of biomedical films.
B32B 7/06 - Liaison entre couches permettant une séparation sans difficultés
A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
B65D 75/30 - Objets ou matériaux enveloppés entre deux feuilles ou flans opposés à bords réunis, p. ex. par adhésifs à pression, pliage, thermosoudage ou soudage
51.
STABLE FORMULATIONS OF ANTIPLATELET AGENTS, OMEGA-3 FATTY ACIDS AND AMYLOSE IN SOFT GELATIN CAPSULES
The present invention relates to a single-dose formulation for oral use of the thyroid hormones triiodothyronine or liothyronine (T3) and tetraiodothyronine or thyroxine (T4) in water-alcohol solution, which is physically and chemically stable, protected against accidental or microbiological contamination, in a container for pharmaceutical use which is squeezable and impermeable to the evaporation of the volatile substances it contains, and the corresponding means for implementing it.
A61J 7/00 - Dispositifs pour administrer les médicaments par voie buccale, p. ex. cuillèresDispositifs pour compter les pilulesDispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
Disclosed is a process for the preparation of chondroitin sulfated at position 3 of GlcA units, comprising the formation of an intermediate consisting of a cyclic orthoester (orthoacetate or orthobenzoate) at positions 4 and 6 of the GalNAc residues of chondroitin in acid form.
The invention relates to the use of an additive to stabilise hyaluronic acid formulated in an aqueous composition against the degrading effect of heat or of enzymes such as hyaluronidase, characterised in that said additive comprises one or more polysaccharides having a molecular weight equal to or greater than 20,000 daltons and solubility in water at least equal to or greater than 1 g/l, the total concentration of said polysaccharide(s) and hyaluronic acid in the composition giving it a viscosity of at least 500 cP, which is particularly suitable for intra-articular, intradermal or intraocular administration to humans or animals.
Disclosed is a process for the production of chondroitin sulphate,wherein N-acetyl-galactosamine residues sulphated at the 4-or 6-positions are present on the same polysaccharide chain.
Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.
C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
59.
COMPOSITIONS AND PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF THYROID HORMONES ABLE TO COMBAT THE ACTION OF SEQUESTRANTS IN THE GASTROINTESTINAL TRACT
The invention concerns the use of a substance chosen among animal or vegetable gelatine, peptones, dextrins, native or modified cyclodextrins, starch, and starch hydrolysates in the preparation of pharmaceutical forms for the oral administration of thyroid hormones to combat the action of sequestrant agents present in the gastrointestinal tract, and related pharmaceutical forms.
The present invention relates to a container for pharmaceutical use for the quantitative release of a single-dose for oral administration of the T3 and T4 thyroid hormones in solution, characterized by the fact of being formed with a plastic material having a Young's modulus between 10 and 80 MPa.
A61J 3/07 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de capsules ou de petits conteneurs similaires à absorber par voie buccale
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY FOR ADMINISTRATION VIA A PATCH FOR EXTERNAL USE, AND COMPOSITION THUS OBTAINED
The present invention relates to a process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, its components including as active principle a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic base chosen from hydroxyethylpyrrolidine or hydroxyethylpiperidine characterized in that said active principle is added to a mixture of one or more of said components, in the form of a solution in water and propylene glycol in a ratio of about 1:1 parts by weight.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
62.
A SUBLINGUAL EFFERVESCENT TABLET OF PROGESTERONE ASSOCIATED WITH CYCLODEXTRIN
A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.
A61K 9/46 - Pilules, pastilles ou comprimés effervescents
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
brevets
